Induction of lymphorecticular neoplasia and malformations by prenatal treatment with 1,3-di(4-sulfamoylphenyl)-triazene in mice.
1,3-Di(4- sulfamoylphenyl )-triazene ( DSPT ), synthesized from two equivalents of sulfanylamide and one equivalent of sodium nitrite, induced specific types of tumors (lymphoreticular neoplasias) in the offspring, when it was given orally to pregnant mice on Days 13-18. Tumor incidences were 6.1, 20.0, and 21.7%, when DSPT was given at 1, 4 and 10% concentration in the diet, respectively, while the control value was 0.8%. DSPT did not induce lung tumors, which are commonly induced by mutagenic carcinogens. DSPT also produced malformations (cleft palate, exencephalus , etc.), when given intraperitoneally on Days 9, 10 and 11. Incidence increased with increasing doses of DSPT , that is, 15.8, 21.1 and 36.7% at doses of 22, 36 and 44 micrograms/g, respectively, while the incidence was 0.3% in the untreated controls. DSPT was found to be non-mutagenic but weakly clastogenic in Drosophila melanogaster.
D000014:Abnormalities, Drug-Induced / Q000473:pathology; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D005260:Female; D005313:Fetal Death; D005870:Giant Cell Tumors / Q000139:chemically induced* / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000139:chemically induced* / Q000473:pathology; D051379:Mice; D008813:Mice, Inbred ICR; D011247:Pregnancy; D013723:Teratogens / Q000633:toxicity*; D014226:Triazenes / Q000633:toxicity*; D000096926:Benzenesulfonamides
D002273:Carcinogens; D013723:Teratogens; D014226:Triazenes; C026587:1,3-di(4-sulfamoylphenyl)triazene; D000096926:Benzenesulfonamides